Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Gavriatopoulou, Maria, Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Eleutherakis-Papaiakovou, Evangelos, Papatheodorou, Athanasios, Kanellias, Nikolaos, Migkou, Magdalini, Fotiou, Despina, Dialoupi, Ioanna, Roussou, Maria, Kokkali, Nikoletta-Aikaterini, Kastritis, Efstathios, Dimopoulos, Meletios A.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Correspondence
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7052253/
https://ncbi.nlm.nih.gov/pubmed/32123158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0297-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados